International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

http://ijpsat.ijsht-journals.org
Vol. 23 No. 2 November 2020, pp. 644-653

Updates of Overactive Bladder (OAB) Management Review

Maged Naser[1], Mohamed M.Nasr[2].and Lamia H.Shehata[3]

[1]Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn ,

[2]King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Surgery ,

[3]Care National hospital. Department of Radiology

Abstract – Overactive bladder disorder (OAB) is characterized as urinary urgency, usually joined by frequent infection or with evident pathology. In this review, we center on late advances in the management of OAB. We look at the proof on the impact of anticholinergic load on OAB patients. Advances in clinical treatment incorporate another beta-3 agonist, vibegron, which is thought to have fewer drug interactions than mirabegron. Treatment of genitourinary condition of the menopause with estrogens and ospemifene have additionally indicated guarantee for OAB. Botulinum toxin has been demonstrated to be a powerful treatment choice. We talk about the new implantable neuromodulators that are available just as specific bladder enervation and laser innovation, Surgeries are bound to be executed to cure UI however are related with more adverse events . In the most recent decade, laser treatment of SUI and of the genitourinary disorder of menopause (GSM) has been indicated a promising treatment technique.

Keywords – (Overactive bladder, Urinary incontinence, Bladder botulinum toxin (Botox) injection, Anticholinergics, Percutaneous tibial nerve stimulation , Sacral neuromodulation, laser treatment).

I. INTRODUCTION

Overactive bladder (OAB) is a disorder characterized by the International Continence Society as "urinary urgency, typically joined by frequency and nocturnal, with or without urgency urinary incontinence (UI), without urinary tract infection (UTI) or different evident pathology." OAB occurs with or without incontinence, referred to as OAB (wet) and OAB (dry), respectively. Around 66% of patients reporting symptoms of urgency and frequency don't have concurrent incontinence (OAB dry), though 33% do encounter incontinence with their symptoms (OAB wet).

Heterogeneity in symptoms and under reporting of symptoms by patients makes the prevalence and rate of overactive bladder hard to set up. The NOBLE Program in 2001 utilized phone studies to determine the prevalence of OAB and discovered prevalence in the United States to be 16.9% in women, with somewhat more than33% of these women having incontinence related with their OAB.[1] Prevalence of symptoms likewise expanded with age. Another survey demonstrated a slighter higher rate of 18.6% for patients reporting these symptoms "regularly," with 28.7% of the adult US population revealing infrequent ("sometimes") OAB symptoms. [2, 3]

Evaluations demonstrate that the adult US population spent an extra $24.9 billion every year to deal with their urinary symptoms with a lot of this consumption, specifically

Corresponding Author: Maged Naser

among institutionalized adults, related to incontinence items (e.g., pads). [2] Estimates from over 10 years prior demonstrate that women aged 60 to 80 are the biggest developing section of the population in the United States, so these assessments of expenses are probably going to increment significantly.

II. Etiology of Overactive Bladder

The reason for overactive bladder isn't well understood known however is believed to be multifactorial in nature. System of neurotransmitters through both autonomic and somatic pathways controls the harmony between these 2 functions. Detrusor over activity, characterized by the International Continence Society as "involuntary detrusor contractions that might be spontaneous or provoked," as seen on urodynamics, [4]

Approximately 90% of detrusor over activity prompting symptoms of urgency and frequency with or without incontinence is idiopathic, without a recognizable etiology. In any case, an assortment of neurologic, lower urinary lot anatomic abnormalities and different problems can cause as well as worsen detrusor over activity.

III. Diagnosis of Overactive Bladder

Overactive bladder is a typical condition that incredibly impacts personal satisfaction, and assessment of the patient should begin with an appraisal of how much the condition impacts the patient's everyday life. Moreover, taking a careful clinical and careful history and a total survey of medications is fundamental to understanding an individual patient's involvement in OAB.

Physical examination can clarify hidden ailments adding to manifestations. The assessment ought to incorporate an overall actual assessment, with uncommon consideration regarding the neurologic and pelvic assessments. Spinal cord segments S2 to S4 are associated with micturition and ought to be assessed appropriately. Pelvic assessment ought to survey for indications of atrophy, pelvic organ prolapsed, pelvic floor muscle quality evaluation, and any anatomic anomalies, including urethral diverticulum.

Relevant laboratory testing incorporates urinalysis and conceivably urine cytology if irritative bladder side effects and significant micro hematuria are available on urinalysis. UTI and persistent irritative bladder conditions can introduce like OAB. Estimation of post void remaining volume (normally <150 mL) can help preclude overflow incontinence.

Urodynamic testing might be shown to additional explore overactive bladder indications in patients with refractory symptoms, past pelvic reconstructive surgical procedure including anti- incontinence operations, neurologic diseases, or voiding dysfunction. Urodynamic testing begins with un instrumented uro flowmetry (estimating flow rate and voiding time) followed by cystometry to assess bladder storage capacity during filling through a catheter to impartially analyze detrusor over activity as confirmed by uninhibited bladder compressions related with urgency. In patients with any concern for a hidden neurologic reason for OAB, electromyography (EMG) can be valuable to assess action of the outer striated urethral sphincter muscles. EMG can assess whether patient exhibits coordination between the outside sphincter which should relax when the detrusor muscle contracts and failure to do so may represent dys-synergic activity, showing a potential upper motor neuron process.

IV. Management of Overactive Bladder

The management of overactive bladder includes treating any underlying reversible medical conditions contributing to the condition, for example, utilization of antibiotics for bladder infections, interceding for stress UI by surgery, weight reduction or medical management, and optimizing glucose control in diabetes, with the objective of advancing toward therapies focused at specific bladder symptoms. A wide assortment of behavioral interventions, pharmacologic agents, and more intrusive alternatives exists for treatment of OAB.

1. Behavioral Modifications and Pelvic Floor Muscle Retraining/physical Therapy

One of the first behavioral interventions utilized in improving symptoms of OAB is bladder retraining. The American Urological Association (AUA)/Society for Urodynamic, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) rules for non-neurogenic OAB in adults published in 2014 supports behavioral modifications as the suggested first-line therapy, in view of current accessible evidence. [5]

This cycle includes quiet instruction on impacts of caffeine and liquid intake and bowel function on symptoms and then on scheduled voiding. A program is created to increase intervals between voids to attempt to suppress urgency and decrease incontinence episodes. The hypothesis behind pelvic floor muscle retraining for asks UI depends on the perception that a detrusor contraction can be hindered by pelvic floor muscle contraction. Expanding the strength of the pelvic floor and ability of a person to hold a contraction can

bring about additional time (maybe only a couple more seconds) to arrive at the toilet and avoid leakage.

Cochrane review published in 2014 assessed the impacts of pelvic floor muscle retraining (PFMT) in UI, both stress and urge incontinence. No randomized controlled examinations looked at urge incontinence only and the impacts of PFMT. In the 3 trials including women with a wide range of UI, all detailed that PFMT was superior to the control group for complete resolution of symptoms. [6]

However, in the study with a larger proportion of women specifically with urge incontinence, the rates of cure were accounted for as lower. Every one of the 3 of the studies reviewed indicated a pattern toward improved personal satisfaction compared with no treatment. Further research into long term adequacy and cost-effectiveness for PFMT is justified. Existing proof is deficient to make any solid suggestions about the best way to deal with PFMT. The treatment isn't normalized nor observed. Furthermore, advantages to utilizing pelvic floor physical treatment in blend with biofeedback has been appeared to diminish symptoms of OAB, yet these intercessions don't keep up their effects at 15 years and can be troublesome schedules for patients to keep up over the long term.[7] Although specific trials for urgency incontinence/overactive bladder side effects and PFMT are required, the evidence overall supports the utilization of pelvic floor muscle treatment as a first-line therapy for symptoms.

2. Medical Treatment

For a long time, ant muscarinic prescriptions have been utilized for treatment of OAB symptoms and are presently suggested by the AUA as the second-line treatment. In spite of the fact that there are 5 subtypes, the muscarinic receptors inside the bladder are basically of the M2 and M3 subtypes. M2 receptor acts to inhibit the sympathetic pathways to the bladder, in this way inhibiting relaxation of the detrusor muscle. When activated, the M3 receptors promote detrusor contractions.

An orderly survey 2012 for the Agency for Health-care Research and Quality examined all the diagnostic studies and therapeutic randomized and nonrandomized contemplates published in English up to that time to determined efficacy and comparative effectiveness among pharmacologic medicines for UI. This study reported that benefits (characterized as less perceived urgency and continence) were accomplished with antimuscarinic drugs, including trospium, solifenacin, fesoterodine, tolterodine, and oxybutynin. Medications for urgency UI exhibited comparable effectiveness. Anticholinergic are contraindicated in patients with narrow angel glaucoma and carry the risk of urinary retention and should be utilized with alert in people with a level of bladder outlet obstruction. All anticholinergic medications were more effective than placebo treatment in accomplishing continence and improving UI, yet the level of advantage was low for all drugs. [8]

Also, Madhuvrata and colleagues [9] in a Cochrane review in 2012 reviewed the literature to look at specific formulations of anticholinergics. Oxybutynin and tolterodine are the 2 most established medications and, in this way, the most contemplated. Adequacy is comparable yet oxybutynin is discounted more frequently secondary to side effects. Extended release formulations for the two drugs carry fewer side effects. Solifenacin and fesoterodine were demonstrated to be more effective than tolterodine.

The bladder contains both alpha-adrenergic and beta-adrenergic receptors and stimulation of these receptors can apply some effect on the bladder and urethra. Alpha-adrenergic agonists (ephedrine, phenylpropanolamine, and pseudoephedrine) increase urethral pressure to diminish incontinence. Beta-adrenergic agonists (isoproterenol and terbutaline) bring about bladder relaxation and decline intravesical pressure. In any case, neither of these alpha-adrenergic or beta-adrenergic agonists has demonstrated to be more effective than placebo. [10]

Food and Drug Administration (FDA) affirmed the utilization of mirabegron for the treatment of OAB. Mirabegron is a b3-adrenergic agonist causing wall relaxation during the filling and capacity period of micturition. Mirabegron was found in 3 separate randomized controlled clinical trials to altogether diminish urinary frequency and incontinence episodes, while essentially expanding bladder capacity. [11–13]

Mirabegron fewer reported side effects than anticholinergic yet adverse effects include hypertension, nasopharyngitis, UTI, and headache. Patients on mirabegron should have their pulse checked and it is contraindicated in patients with uncontrolled hypertension. Like anticholinergic, b3-adrenergic agonists can increase the risk of urinary retention so should be utilized with alert in patients with clinically significant bladder outlet obstruction.

Anticholinergic have a high rate of discontinuation because of results. There is a high discontinuation rate with just 18% of patients proceeding with antimuscarinic medicine after 6 months.[14] newer drugs like the b3-adrenergic agonist mirabegron are better tolerated, however long term use keeps on being problematic.

3. Botulinum Toxin

A Cochrane review published in 2011 looked at the results of Botox A utilization in 19 distinct studies, generally treating neurogenic OAB, yet a few for treatment of idiopathic OAB. Each of the 19 examinations exhibited improvement in symptoms utilizing Botox infusions compared and placebo treatment. The EMBARK preliminary (randomized controlled preliminary [RCT] comparing Botox and placebo treatment) indicated a reduction in the day by day frequency of UI episodes versus placebo treatment (2.65 versus 0.87, P<0.001) and 22.9% versus 6.5% of patients turned out to be totally continent. On a botulinum toxin, an improved patient wellbeing related personal satisfaction over different measures (P<0.001). [15]

The Cochrane review likewise found that higher dosages (300 units) were discovered to be more effective yet had more side effects, specifically urinary retention. The review likewise evaluated strategy for infusion and verified that sub urothelial infusion had comparable adequacy to intra detrusor infusions. Regarding measurements, the information uncovered that the length of impact of the toxin fluctuates among patients and is dose-dependent. Patients getting multiple doses didn't seem to become refractory. [16]

The ABC preliminary by Visco and colleagues [17] for the Pelvic Floor Disorders Network was a double blinded RCT comparing anticholinergic treatment with bladder botulinum toxin infusions. Women assigned to the anticholinergic were permitted to increase dose of medication and change to an alternate anticholinergic relying upon their symptom control, which mimics common practice. Anticholinergic and Botox infusions were appeared to have comparative decreases in number of urge incontinence episodes every day; anticholinergic diminished 5.0 to 3.4 and Botox diminished 5.0 to 3.3. Complete resolution of symptoms happened in 13% of patients in the anticholinergic arm and 27% of the patients who got Botox. The two treatments had comparative degrees of enhancement for personal satisfaction estimations. Anticholinergic were related with more noteworthy rates of dry mouth and Botox had higher rates of voiding difficulty requiring intermittent self-catheterization and UTIs.

On a botulinum toxin A has a worthy wellbeing profile. Most normal unfavorable impacts incorporate UTIs and urinary retention requiring self-catheterization (ordinarily short term). The rate of UTI goes from 2% to 32%. [18] UTIs are regularly connected with higher residual volumes. Several contemplates have demonstrated expanded risk of de novo for self-catheterization (ISC) with higher dosages of toxin infused. Popat and colleagues [19] revealed a de novo risk of ISC of 69% with infusion of 300 units and 19% with infusion of 200 units. The ABC preliminary announced a rate of 5% for ISC with utilization of 100 units infused into the bladder detrusor muscle.

Systemic reactions including spasticity or chronic pain is very uncommon occasions with bladder infusion of Botox.

Per the AUA/SUFU rules from 2014, Botox infusions for OAB are viewed as third-line treatment for patients who have bombed first-line (social changes) and second-line treatment (antimuscarinic prescriptions) or are not candidates for anticholinergic medications.[5] Patients must be eager to go through the technique and acknowledge the risk of conceivable requirement for intermittent self-catheterization. In general, the review of the use of Botox for overactive bladder shows that Botox has an average duration of impact of 6 to 9 months. The length of impact is both patient-dependant and dose-dependent. Higher doses (200–300 UN) accompany higher rates of retention. A meta-investigation of studies that followed patients utilizing Botox long term showed no loss of efficacy for as long as 10 years of treatment and no decrease in effect or development of tolerance. [18] Schmid and colleagues [20] indicated that among patients with idiopathic detrusor over activity, poor responders to Botox were bound to have low pretreatment detrusor compliance (<10 mL/cm H2O) and a maximum bladder limit of under 100 mL. These outcomes were like discoveries revealed by Compe' rat and colleagues [21] for neurogenic detrusor activity.

The accessible exploration on Botox intradetrusor infusions by its utilization for overactive bladder indications. The data show a decline in the troublesome manifestations of incontinence and urinary retention. Despite the fact that the risk of urinary maintenance causing UTI or requirement for self-catheterization is low, it stays a significant risk factor to examine with patients. Long-term informationupholdsit's proceeded with use; however patients likewise should know that recurrent infusions are not out of the ordinary.

4. Percutaneous Tibial Nerve Stimulation

Percutaneous tibial nerve stimulation (PTNS) is a minimally invasive, outpatient treatment that has been appeared to diminish manifestations identified with OAB. The The reported rates of success for PTNS were variable (54.5%–79.5%) for treating OAB system includes setting a little needle electrode into the lower inner aspect of one or the other leg near the medial malleolus. The electrode is associated with a trigger that creates an electrical pulse, which at that point goes to the sacral nerve plexus through the

tibial nerve. The treatment course includes 12 week after week 30-minute sessions, at times requiring month to month support meeting. The system isn't painful and no side effects have been appeared. Like sacral neuromodulation, getting to the posterior tibial nerve stimulates sensory afferent nerves, yet PTNS does as such in a less-invasive way compared with direct sacral neuromodulation.

Side effects among these trials.[22] Another meta-investigation by Burton and colleagues[23] found that patients who got PTNS were 7 times bound to have successful treatment compared with placebo treatment. Peters and colleagues [24] developed a sham procedure and performed a RCT comparing PTNS with the sham technique. They statically significant improvement in bladder symptoms with 54.5% of patients getting PTNS detailing tolerably or especially improved response compared with 20.9% of sham subjects from baseline (P<.001). Peters and colleagues[25]also performed a RCT comparing PTNS with tolterodine 4 mg extended release and demonstrated a statistically significant improvement in OAB symptoms in the PTNS group compared with the sham procedure group(79.5% reporting cure or improvement versus 54.8%, P 5 .01). Besides, Finazzi-Agro' and colleagues[26]Prospective study, double blinded RCT differentiating PTNS and placebo treatment and found that 71% of those in the PTNS group were considered "responders" to treatment (a decline of at any rate 50%of urge incontinence episodes) versus 0% in the placebo treatment group They moreover noted a significant basic improvement in number of incontinence episodes, number of voids, voided volume and incontinence quality of life (I-QoL) scores in the PTNS group; none of which was basically improved in the placebo treatment group.[26]

PTNS is depicted excessively suffered in both meta-examinations and no serious adverse events were reported. [22,23] infrequent transient side effects included pain, bruising, tingling, or bleeding at insertion site. An examination by MacDiarmid and colleagues [27, 28] followed PTNS for 6 and 12 months after completing the 12 sessions of PTNS to evaluate the long term efficacy. Overactive bladder overview result earnestness was basically improved from 12 weeks to a year (p 0.01) similarly as from 6 to a year (p 0.01), current composition on PTNS shows that it is a safe, effective procedure for treatment of OAB and effects have been shown to persist up to a year anyway longer-term data are required.

5. Sacral neuromodulator

Investigations, incontinent scenes every day and pad utilization altogether improved Sacral neuromodulator is a technique for treating overactive bladder symptoms that are refractory to other methods. Hypothetically, sacral neuromodulation is thought to act by activation of afferent sacral nerve fibers that inhibit parasympathetic motor neurons, in this way preventing detrusor contractions. The procedure is frequently 2-staged; where initial an electrode is set through a sacral foramen to lie near a sacral nerve, typically S3. The patient goes through a test stage as a set of programmed electrical impulses are conveyed to the electrode within a set range. In the event that the patient has adequate response to the stimulation (decrease in number of voids and episodes of incontinence), at that point the patient will go through the second stage of the method. Around 30% of patients get practically no reaction during this stage and don't proceed to have the subsequent stage implanted Stage 2 includes associating the electrode by means of a cable under the skin to the implantable impulse generator. The technique requires the operation room and can be costly.

Studies by both van Kerre broeck and colleagues [29] and Groen and colleagues [30] followed patients being treated for OAB with sacral neuromodulation over the long term and furthermore checked for adverse effects. Van Kerrebroeck and colleagues [29] collected data for 5years. They announced measurably significant declines in number of incontinence episodes every day (9.6 6.0 diminished to 3.9 4.0) and number of voids every day (19.3 7.0 diminished to 14.8 7.6). This study announced no life threatening or irreversible effects more than 5 years. They characterized "achievement" as a 50%improvement from baseline and detailed achievement rates of 68% for incontinence and 56% for urinary recurrence. Groen and colleagues [30] also followed patients for a very long time and characterized "achievement" as a 50% reduction in incontinence episodes or pads utilized every day. At 1month, 87% of patient's revealed achievement and this diminished to 62% by 5 years. They revealed 57 unfavorable occasions more than 5 years however none of the events were severe, per the Clavier reviewing grading system.

Siddiqui and colleagues[31] published in 2010 looked to survey accessible examination in regards to the efficacy, especially with the development of new leads, just as the safety, of sacral neuromodulation devices, Seven investigations were of adequately acceptable quality to be remembered for this survey of sacral neuromodulation efficiency. In these after sacral nerve incitement. Six

examinations were assigned as "acceptable" for audit of antagonistic events. With the new utilization of tined leads, careful modification rates went from 3% to 16%, which is a lessening from the nontined leads. Adverse event rates with tined leads are lower than previously published appraisals utilizing nontined leads.

6. Laser Treatments for Stress Urinary Incontinence

The primary pilot study with respect to Er: YAG laser in the treatment of SUI began on September, 2009 [32], the quality of life (QoL) was evaluated with oneself revealed International Consultation on Incontinence Questionnaire–Urinary Incontinence Short Form (ICIQ-UI SF) [33], where a greatest score of 21 represent permanent incontinence.

At the first follow-up measurement (1month after the intervention) the number of totally continent patients expanded from zero to 17/52 (42.3% cotontient). At the second follow-up, 2–6 months after the intervention, 18/47 (38.3% continent) had an ICIQ-UI score =0. From baseline to the second follow up, 34/47 (72.3%) members experienced improvement, though 11/47 (23.4%) encountered no adjustment in the ICIQ-UI score, and two (4.3%) experienced intensifying of manifestations. No major unfavorable occasions were seen or revealed over the span of laser treatment and the subsequent period. The uncommon rare mild symptoms revealed side effects, for example, slight edema, and transient urgency vanished immediately following 8 days.

Ogrinc BU et al. published a study analyzed SUI (66%) and urgency urinary incontinence (MUI, 34%) [34], treated by the uniform Er: YAG laser convention. Subsequent meet-ups were performed at 2 month, 6 months, and a year after the method. The outcomes depended on the Incontinence Severity Index (ISI) and the decrease in ICIQ-UI SF scores. One year after laser treatment, 77% of the SUI patients and just 34% of the MUI stayed continent.

In another study [35] utilizing a similar Er m: YAG protocol for SUI, urodynamic contemplates, pad testing, and lower urinary tract syndrome (LUTS were surveyed when treatment. The authers inferred that the method for mild SUI was successful at half year development, however not in the patients with an underlying pad weight >10 g. Besides, and it improved LUTS, QoL. Urodynamic values didn't contrast over the course of events

In spite of the fact that the development was distinctly up to the 6th month, the authers summed up that IncontiLase™ ought not to supplant mid-urethral sling (MUS) surgical procedure as the standard treatment for SUI patients who neglect to improve following first-line treatment. Furthermore, the authers focused on that the infusion of bulking agents has been accounted for to have a cure rate of 53–73.2%, which is superior to the cure rate of 39.3% they accomplished at a half year with IncontiLase™. Taking everything into account, the authors conceded that, in light of its insignificantly invasive nature and the absence of significant effects, the IncontiLase™ strategy might be utilized as an elective treatment for mild SUI cases.

In a long term, a two year subsequent examination [36] on 114 postmenopausal women experiencing SUI, the vaginal erbium laser (VEL) treatment induced a significant decrease in baselione ICIQ-SF scores of 12.2 ± 2.5. The ICIQ-UI SF scores remained fundamentally ($p<0.01$) lower than the basal values after 1 (4.8 ± 1.8), 3 (6.2 ± 1.9), 6 (7.0 ± 2.3), and 12 (8.0 ± 1.8) months after the last VEL application. Nonetheless, the scores after 18 (9.3 ± 2.7) and 24 (9.9 ± 2.8) months from the last VEL application were not significantly different from the baseline values.

Other observational studies where in Er: YAG was utilized for mild to moderate SUI additionally indicated improvement in SUI symptoms [37-39]. Until this point, there is just a single patient-blinded randomized controlled trial for SUI [40] comprising of 114 women getting a solitary meeting of no ablative warm just Er: YAG laser treatment. This examination reports improvement of SUI side effects, QoL (ICIQ-UI SF), (PISQ12 and FSFI) in premenopausal parous women. A 21.4% (12/56) of the laser group patients were continent 3 months after treatment as indicated by ICIQ-UI SF (score = 0) in contrast with just 3.6% (2/56) continent in the sham control gathering. The covariates age, BMI, and equality had no huge impact on the result. All pelvic floor muscle factors, gotten from perineometry examines (span and most extreme weight), indicated a significant improvement in the laser gathering yet not in the sham control group.

Carbon (CO_2) laser has been utilized for GSM treatment, especially focusing in on the vulvovaginal atrophy segment [41]. Isaza et al. [42] utilized the SmartXide2 V2LR partial micro ablative CO_2 laser framework, in an imminent report on 161 postmenopausal women experiencing mild SUI.

The patients got four sessions 30–45 days separated. SUI was assessed utilizing the 1-h pad test and the ICIQ-UI SF at pattern and at 12, 24, and three years. The basal ICIQ-UI SF score (14.34 ± 2.65) essentially diminished at 12 (7.09 ± 1.1, $p < 0.001$), 24 (7.49 ± 0.94, $p < 0.001$), and three years (6.76 ± 0.82, $p < 0.001$) of development , the 1-hour pad test diminished from 9.89 ± 0.57 g at standard to 3.52 ± 1.89 g, 3.55 ± 1.88 g, and 3.72 ± 2.05 g at 12, 24, and three years,

separately (all $p < 0.001$). Histology examination which was done previously and a month and a half after the main treatment demonstrated basically thicker epithelium with a higher population of intermediate and suprficial cell shedding. CO2 laser ablative vaginal treatments could increase the possibility of vaginal scarring and infection. Utilizing the nonablative laser treatment, possible side effects could be reduced [40].

The significant improvement in dyspareunia, dryness, and burning, tingling, dysuria, and SUI scores was assessed in the prospective observational study incorporating postmenopausal women with moderate to extreme clinical indications of GSM [43].

The women got intravaginal therapy with CO2 laser system for 3 consecutive months.

The authors noticed that urinary side effects improved, as the scores of the urinary and

QoL polls diminished altogether. ICIQ-UI SF at the pattern was 8.1±5.6 versus 3.4±4.3 at the 3-month development. All members demonstrated a > 5-point improvement in the King's Health Questionnaire (KHQ) score, which incorporates psychometric parts of UI, the authors concluded that the factors predective of ideal CO2 laser treatment,[44]

A report [45] distinguished Indicators for the section of patients accomplishing ideal Er:YAG laser treatment Momentary results. The best outcomes after Er: YAG laser treatment of SUI ought Normal in more youthful women (< 47.5 years) with a body mass index of < 23.3, and ICIQ-UI at a baseline of < 10.

Nonetheless, regardless of the thorough choice of patients, laser treatment won't prevail in a specific gathering. Specifically, SUI is incited by urethral hypermobility not just because of weakness or interruption of the pelvic floor musculature and/or pubouretheral ligament yet additionally because of the debilitating of the urethral sphincter, bringing about more severe intrinsic sphincter dificiency (ISD) [46].

The urethral sphincter function relies upon the muscular part, the rhabdosphincter, reaching out along 60–70% of the urethral length, and the mucosal or intrinsic component, extending out over the urethra and adding to urethral closure. Women whose urodynamic contemplates indicated a maximal urethral closure pressure (UCP) of fewer than 40 cm H2O got three fractional CO2 laser treatments a month separated , urodynamic reexamination, a 3 months after the treatment, demonstrated an expansion in maximal UCP of 19-33 cm H2O to 45-73 cm H2O.[47]

V. Conclusion

Overactive bladder adversely impacts the personal satisfaction for an enormous number of patients and is a large economic burden because of fundamental expenses of medical services supplier visits, utilization of pads and other incontinence supplies, drugs, and surgeries. Alongside behavioral adjustments, anticholinergic have for quite some time been the mainstay of treatment. In any case, these meds are oftentimes stopped after some time as a result of side effects and incomplete resolution of symptoms. Arising b3-adrenergic agonists furnish a medicine choice with a wager term result profile. Newer treatment choices include a botulinum toxin a bladder injections, PTNS, and sacral neuromodulation. Every one of these options shows promise in initial research; however more long term assessment and comparative studies are expected to suggest one technique for treatment over another and to figure out which patient would most benefit by every treatment choice. "Laser" in medicine, represents various assorted devices. They transmit diverse energy at various frequencies and produce various impacts in various tissues. Right now there is no accessible published study with various laser devices for SUI and GSM treatment. Notwithstanding, long term well designed studies are as yet expected to disclose the effectiveness of laser and different EBDs (energy based devices) in SUI and GSM treatment.

VI. Conflict of interest

All authors declare no conflicts of interest.

VII. Authors contribution

Authors have equally participated and shared every item of the work.

References

[1]- Stewart, W. (2001). The prevalence and impact of overactive bladder in the US: results from the NOBLE program. *Neurourol Urodynam.*, *20*, 406-408.

[2]- Onukwugha, E., Zuckerman, I. H., McNally, D., Coyne, K. S., Vats, V., & Mullins, C. D. (2009). The total economic burden of overactive bladder in the United States: a disease-specific approach. *Am J Manag Care*, *15*(4 Suppl), S90-7.

[3]- Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004 Mar; 63(3):461-5. Doi: 10.1016/j.urology.2003.10.037. PMID: 15028438.

[4]- Messelink, B., Benson, T., Berghmans, B., Bo, K., Corcos, J., Fowler, C., & Pemberton, J. (2005). Standardization of terminology of pelvic floor muscle function and dysfunction: report from the pelvic floor clinical

assessment group of the International Continence Society. *Neurourology and Urodynamics: Official Journal of the International Continence Society*, *24*(4), 374-380.

[5]- Pratt, T. S., & Suskind, A. M. (2018). Management of overactive bladder in older women. *Current urology reports*, *19*(11), 92.

[6]- Dumoulin, C., Hay-Smith, J., Habée-Séguin, G. M., & Mercier, J. (2015). Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women: a short version Cochrane systematic review with meta-analysis. *Neurourology and urodynamics*, *34*(4), 300-308.

[7]- White, N., & Iglesia, C. B. (2016). Overactive bladder. *Obstetrics and Gynecology Clinics*, *43*(1), 59-68.

[8]- Shamliyan, T., Wyman, J., & Kane, R. L. (2012). Nonsurgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness.

[9]- Madhuvrata, P., Cody, J. D., Ellis, G., Herbison, G. P., & Hay-Smith, E. J. C. (2012). Which anticholinergic drug for overactive bladder symptoms in adults. *Cochrane Database of Systematic Reviews*, (1).

[10]- Nabi, G., Cody, J. D., Ellis, G., Hay-Smith, J., & Herbison, G. P. (2006). Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. *Cochrane database of systematic reviews*, (4).

[11]- Kleeman, S. D., & Karram, M. M. (2007). Overactive bladder syndrome and nocturia. In *Urogynecology and reconstructive pelvic surgery* (pp. 353-376). Mosby.

[12]- Fantl, J. A., Wyman, J. F., McClish, D. K., Harkins, S. W., Elswick, R. K., Taylor, J. R., & Hadley, E. C. (1991). Efficacy of bladder training in older women with urinary incontinence. *Jama*, *265*(5), 609-613.

[13]- Jarvis, G. J., & Millar, D. R. (1980). Controlled trial of bladder drill for detrusor instability. *British Medical Journal*, *281*(6251), 1322.

[14]- Kelleher, C. J., Cardozo, L. D., Khullar, V., & Salvatore, S. (1997). A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. *BJOG: An International Journal of Obstetrics & Gynaecology*, *104*(9), 988-993.

[15]- Nitti, V. W., Dmochowski, R., Herschorn, S., Sand, P., Thompson, C., Nardo, C., & EMBARK Study Group. (2013). OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. *The Journal of urology*, *189*(6), 2186-2193.

[16]- Duthie, J. B., Vincent, M., Herbison, G. P., Wilson, D. I., & Wilson, D. (2011). Botulinum toxin injections for adults with overactive bladder syndrome. *Cochrane Database of Systematic Reviews*, (12).

[17]- Visco, A. G., Brubaker, L., Richter, H. E., Nygaard, I., Paraiso, M. F. R., Menefee, S. A., ... & Spino, C. (2012). Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. *New England Journal of Medicine*, *367*(19), 1803-1813.

[18]- Yokoyama, T., Chancellor, M. B., Oguma, K., Yamamoto, Y., Suzuki, T., Kumon, H., & Nagai, A. (2012). Botulinum toxin type A for the treatment of lower urinary tract disorders. *International Journal of Urology*, *19*(3), 202-215.

[19] Popat, R., Apostolidis, A., Kalsi, V., Gonzales, G., Fowler, C. J., & Dasgupta, P. (2005). A comparison between the response of patients with idiopathic detrusor over activity and neurogenic detrusor over activity to the first intradetrusor injection of botulinum-A toxin. *The Journal of urology*, *174*(3), 984-989.

20]-Schmid DM, Sauermann P, Werger M, et al. Experience with 100 cases treatedwith botulinum-A toxin injections in the detrusor muscle for idiopathic overactivebladdersyndromerefractorytoanticholinergics.JUrol2006; 176:177–85

[21]- Compérat, E., Reitz, A., Delcourt, A., Capron, F., Denys, P., & Chartier-Kastler, E. (2006). Histologic features in the urinary bladder wall affected from neurogenic over activity—a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. *European urology*, *50*(5), 1058-1064.

[22]- Gaziev, G., Topazio, L., Iacovelli, V., Asimakopoulos, A., Di Santo, A., De Nunzio, C., & Finazzi-Agrò, E. (2013). Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. *BMC urology*, *13*(1), 1-11.

[23]- Burton, C., Sajja, A., & Latthe, P. M. (2012). Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta-analysis. *Neurourology and urodynamics*, *31*(8), 1206-1216.

[24]- Peters, K. M., Carrico, D. J., Perez-Marrero, R. A., Khan, A. U., Wooldridge, L. S., Davis, G. L., & MacDiarmid, S. A. (2010). Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. *The Journal of urology*, *183*(4), 1438-1443.

[25]- Peters, K. M., MacDiarmid, S. A., Wooldridge, L. S., Leong, F. C., Shobeiri, S. A., Rovner, E. S., ... & Feagins, B. A. (2009). Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from

the overactive bladder innovative therapy trial. *The Journal of urology*, *182*(3), 1055-1061.

[26]- Finazzi-Agrò, E., Petta, F., Sciobica, F., Pasqualetti, P., Musco, S., & Bove, P. (2010). Percutaneous tibial nerve stimulation effects on detrusor over activity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *The Journal of urology*, *184*(5), 2001-2006.

[27]- Peters, K. M., Carrico, D. J., Perez-Marrero, R. A., Khan, A. U., Wooldridge, L. S., Davis, G. L., & MacDiarmid, S. A. (2010). Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. *The Journal of urology*, *183*(4), 1438-1443.

[28]- Herbison, G. P., & Arnold, E. P. (2009). Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. *Cochrane database of systematic reviews*, (2).

[29]- van Kerrebroeck, P. E., van Voskuilen, A. C., Heesakkers, J. P., Lycklama á Nijholt, A. A., Siegel, S., Jonas, U., ... & Cappellano, F. (2007). Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. *The Journal of urology*, *178*(5), 2029-2034.

[30]- Groen, J., Blok, B. F., & Bosch, J. R. (2011). Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. *The Journal of urology*, *186*(3), 954-959.

[31]- Siddiqui, N. Y., Wu, J. M., & Amundsen, C. L. (2010). Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. *Neurourology and urodynamics*, *29*(S1), S18-S23.

[32]- Fistonić, N., Fistonić, I., Lukanovič, A., Guštek, Š. F., Turina, I. S. B., & Franić, D. (2015). First assessment of short-term efficacy of Er: YAG laser treatment on stress urinary incontinence in women: prospective cohort study. *Climacteric*, *18*(sup1), 37-42.

[33] Klovning, A., Avery, K., Sandvik, H., & Hunskaar, S. (2009). Comparison of two questionnaires for assessing the severity of urinary incontinence: the ICIQ-UI SF versus the incontinence severity index. *Neurourology and Urodynamics: Official Journal of the International Continence Society*, *28*(5), 411-415.

[34]- Ogrinc, U. B., Senčar, S., & Lenasi, H. (2015). Novel minimally invasive laser treatment of urinary incontinence in women. *Lasers in surgery and medicine*, *47*(9), 689-697.

[35]- Tien, Y. W., Hsiao, S. M., Lee, C. N., & Lin, H. H. (2017). Effects of laser procedure for female urodynamic stress incontinence on pad weight, urodynamics, and sexual function. *International urogynecology journal*, *28*(3), 469-476.

[36]- Gambacciani, M., Levancini, M., Russo, E., Vacca, L., Simoncini, T., & Cervigni, M. (2018). Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. *Climacteric*, *21*(2), 148-152.

[37]- Pardo, J. I., Sola, V. R., & Morales, A. A. (2016). Treatment of female stress urinary incontinence with Erbium-YAG laser in non-ablative mode. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, *204*, 1-4.

[38]- Leshunov, E. V., & Martov, A. G. (2015). Application of laser technologies for treatment of urinary stress incontinence in women of reproductive age. *Urologiia (Moscow, Russia: 1999)*, (1), 36-40.

[39]- Neimark, A. I., Yakovleva, A. Y., & Lapii, G. A. (2018). Outcomes of ER: YAG LASER treatment of stress urinary incontinence in women. *Urologiia (Moscow, Russia: 1999)*, (2), 20-25.

[40]- Blaganje, M., Šćepanović, D., Žgur, L., Verdenik, I., Pajk, F., & Lukanović, A. (2018). Non-ablative Er: YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, *224*, 153-158.

[41]- Tadir, Y., Gaspar, A., Lev-Sagie, A., Alexiades, M., Alinsod, R., Bader, A., & Iglesia, C. B. (2017). Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. *Lasers in surgery and medicine*, *49*(2), 137-159.

[42]- Isaza, P. G., Jaguszewska, K., Cardona, J. L., & Lukaszuk, M. (2018). Long-term effect of thermo ablative fractional CO 2 laser treatment as a novel approach to urinary incontinence management in women with genitourinary syndrome of menopause. *International urogynecology journal*, *29*(2), 211-215.

[43]- Pitsouni, E., Grigoriadis, T., Tsiveleka, A., Zacharakis, D., Salvatore, S., & Athanasiou, S. (2016). Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: an observational study. *Maturitas*, *94*, 131-136.

[44]- Golubnitschaja, O., Kinkorova, J., & Costigliola, V. (2014). Predictive, preventive and personalised medicine as the hardcore of 'Horizon 2020': EPMA position paper. *EPMA Journal*, *5*(1), 6.

[45]- Fistonić, I., & Fistonić, N. (2018). Baseline ICIQ-UI score, body mass index, age, average birth weight, and perineometry duration as promising predictors of the short-term efficacy of Er: YAG laser treatment in stress urinary

incontinent women: A prospective cohort study. *Lasers in surgery and medicine*, *50*(6), 636-643.
[46]- Lane, T. M., & Shah, P. J. R. (2000). Valsalva leak point pressure in the evaluation of stress urinary incontinence. *Braz J Urol*, *26*, 420-425.
[47]- McGuire, E. J., Fitzpatrick, C. C., Wan, J., Bloom, D., Sanvordenker, J., Ritchey, M., & Gormley, E. A. (1993). Clinical assessment of urethral sphincter function. *The Journal of urology*, *150*(5 Part 1), 1452-1454.
[48]- Patel, F. (2017). The effects of RF excited fractional CO2 laser on the vaginal canal in treating stress urinary incontinence [2G]. *Obstetrics & Gynecology*, *129*(5), 71S-72S.